Article Text
Correction
Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
Statistics from Altmetric.com
Nguyen LS, Bretagne M, Arrondeau J, et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J ImmunoTher Cancer 2022;10:e004699. doi: 10.1136/jitc-2022-004699.
This article has been corrected since it was first published online. In the ‘Case-report’ section, the dosage for intravenous abatacept in combination with oral ruxolitinib has been corrected to ‘15 mg two times daily’.